Home » Newsletters » BioWorld Science

BioWorld Science

April 4, 2007

View Archived Issues

Emisphere reports data on oral delivery of GLP-1 and PYY

Alpharma licenses novel technology from Tris Pharma

Enzon studies HIF-1 alpha antagonist in phase I trial

Safety and pharmacokinetics established for XTL-6865 in HCV

MedImmune licenses reverse genetics intellectual property to sanofi pasteur

VioQuest adds two new products to pipeline

Athersys achieves commercial collaboration milestones

Pivotal study of romidepsin in CTCL cleared to continue

Takeda acquires rights to R-851 from 3M

Galapagos achieves milestones in GSK osteoarthritis collaboration

Development of Pevion's malaria vaccine supported by E.U. grant

Phase II study of LE-SN38 misses primary tumor response endpoint

Topical interferon alpha-2b shows clinically efficacious response in LSIL

Berlex reports on novel CCR5 antagonists

Recent patents impart new therapeutic agents for cancer

IND clearance sought for phase II ophthalmic study of Tbeta4 eye drops

Parkinson's disease drug pergolide withdrawn

EMEA recommends restrictions on use of Ketek

Lutetium-177-labeled monoclonal antibody cG250 appears safe in renal cell carcinoma

V-HeFT I and II formulations of isosorbide dinitrate/hydralazine not bioequivalent

Nicotine patch appears safe for use in coronary artery disease patients

Novel KCNQ2 channel opener shows antiepileptic activity in mice

Novel treatment options for inflammatory disorders claimed in recent GSK and Palau patents

Novel therapeutic agents for immunological disorders disclosed in recent patents

Cardiome Pharma updates status of key programs

Lucentis launched in the U.K.

Transition receives fast track designation for Alzheimer's disease drug candidate

Santen seeks European approval of tafluprost

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...